Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: The difficulties in the identification of C. auris and the delays in the implementation of infection control precautions contribute to outbreaks. This study analyzed 10 patients with COVID-19 and C. auris candidemia, their characteristic and clinical features and phylogenetic features, and the antifungal susceptibilities of the isolates.

Method: C. auris were detected in the COVID-19 ICU of a university hospital between January and August 2021. Identification to species level was performed using MALDI-TOF MS. Antifungal susceptibilities were determined by the Sensititre YeastOne YO10 panel. The isolates were whole genome sequenced to assess genetic relatedness and a phylogenetic tree was drawn including various C. auris clades.

Results: The mean growth time in blood cultures was 38.8 h. C. auris candidemia developed on the average 27th day of ICU admission. All were susceptible to anidulafungin and micafungin, while they were resistant to fluconazole and amphotericin B. Only three isolates were found to be resistant to caspofungin. All patients died. With the WGS method, all isolates were found in a close resemblance to each other in terms of total nucleotide similarity (with a minimum of 96% pairwise alignment). Our isolates showed the closest similarity to South Asian clade (Clade I).

Conclusions: This study is the first to evaluate the phylogenetic characteristics of C. auris using WGS and to determine antifungal susceptibilities in Türkiye on COVID-19 patients. The mortality rate was very high in patients who have both COVID-19 and C. auris candidemia.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11046-023-00782-6DOI Listing

Publication Analysis

Top Keywords

auris candidemia
12
antifungal susceptibilities
12
auris
8
patients covid-19
8
covid-19 auris
8
covid-19
5
isolates
5
nosocomial infection
4
infection auris
4
auris covid-19
4

Similar Publications

Introduction: Candida auris is a yeast that has a high mortality rate in critically ill patients and is resistant to many antifungal agents enhancing its clinical importance. Our study identifies the risk factors for C. auris invasive infection, antifungal susceptibility, and outcomes.

View Article and Find Full Text PDF

Candidemia, a common hospital-acquired bloodstream infection, is associated with significant mortality, particularly in cases involving (). The Middle East, including Saudi Arabia, has seen an increasing number of invasive infections. This review examines the epidemiology, risk factors, antifungal susceptibility, clinical manifestations, and mortality associated with , based on published literature from Saudi Arabia.

View Article and Find Full Text PDF

In two cohorts of patients colonized with C. auris in New York State and Chicago, those who progressed to C. auris bloodstream infection had co-morbidities, including respiratory failure and mechanical ventilation, co-colonization with multidrug-resistant organisms, and extensive healthcare facility admissions, devices, and procedures.

View Article and Find Full Text PDF

Invasive Candidiasis in Contexts of Armed Conflict, High Violence, and Forced Displacement in Latin America and the Caribbean (2005-2025).

J Fungi (Basel)

August 2025

Infectious Diseases Service, Clínica Sebastian de Belalcázar, Clínica Colsanitas, Keralty Group, Cali 760042, Colombia.

Invasive candidiasis (IC), characterized by the most common clinical manifestation of candidemia, is a fungal infection with a high mortality rate and a significant impact on global public health. It is estimated that each year there are between 227,000 and 250,000 hospitalizations related to IC, with more than 100,000 associated deaths. In Latin America and the Caribbean (LA&C), the absence of a standardized surveillance system has led to multicenter studies documenting incidences ranging from 0.

View Article and Find Full Text PDF

(now ) is an emerging pathogen that causes nosocomial candidemia, particularly in intensive care unit (ICU) settings. Its high resistance rates, prolonged environmental persistence, and outbreak potential underscore the need for robust comparative studies with non- species (NACS). In this retrospective, case-control study, adult ICU patients with candidemia were enrolled between April 2022 and October 2024.

View Article and Find Full Text PDF